Press releasePRNewswire
Citius Oncology
CTOR · NASDAQ
$0.671−$0.01 (−1.47%)TodayMarket closed ·
Prev close $0.681
Latest news
- Press releasePRNewswire
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
- Press releasePRNewswire
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
- Press releasePRNewswire
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
- Press releasePRNewswire
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
- Press releasePRNewswire
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
- Press releasePRNewswire
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
- Press releasePRNewswire
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
- Press releasePRNewswire
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
- Press releasePRNewswire
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
- News
Earnings Breakdown: Citius Oncology Q1
- News
Citius Oncology Q1 Earnings Summary & Key Takeaways
- Press releasePRNewswire
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Press releasePRNewswire
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
- Press releasePRNewswire
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
- Press releasePRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
- NewsMohd Haider
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
- Press releasePRNewswire
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Press releasePRNewswire
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.